CN104887973A - Traditional Chinese medicine composition for treating acute catarrhal conjunctivitis with cough - Google Patents
Traditional Chinese medicine composition for treating acute catarrhal conjunctivitis with cough Download PDFInfo
- Publication number
- CN104887973A CN104887973A CN201510389925.4A CN201510389925A CN104887973A CN 104887973 A CN104887973 A CN 104887973A CN 201510389925 A CN201510389925 A CN 201510389925A CN 104887973 A CN104887973 A CN 104887973A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- cough
- traditional chinese
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the field of traditional Chinese medicines, relates to traditional Chinese medicine compositions and medicinal use thereof and particularly relates to a traditional Chinese medicine composition for treating acute catarrhal conjunctivitis with cough and application thereof. The traditional Chinese medicine composition for treating acute catarrhal conjunctivitis with cough, provided by the invention, contains the following ingredients in parts by weight: 15 parts of giant knotweed, 6 parts of rhizoma coptidis, 10 parts of lycopodium clavatum, 10 parts of lilies, 10 parts of artemisia capillaris, 20 parts of rhizoma acori gramine, 20 parts of hyacinth bletilla, 10 parts of lithospermum erythrorhizon, 5 parts of herba violae, 5 parts of spatholobus stem and 10 parts of flos chrysanthemi indici. The traditional Chinese medicine composition has a very good treatment effect on the treatment of acute catarrhal conjunctivitis with cough, thereby having a remarkable clinical popularization value.
Description
Technical field
The invention belongs to field of medicaments, be specifically related to a kind of Chinese medicine composition and the application as conjunctivitis medicine thereof.
Background technology
Conjunctivitis (conjunctivitis) is the commonly encountered diseases of ophthalmology, be conjunctival tissue in the effect of the extraneous and body oneself factor general designation of inflammatory reaction that occurs.Because most of conjunctiva directly contacts with the external world, therefore the stimulation of infectious (as antibacterial, virus and chlamydia etc.) and non-infectious factor (wound, chemical substance and physical factor etc.) in surrounding is easily subject to, and the blood vessel of conjunctiva and lymphoid tissue are enriched, the antigen in self and the external world easily makes its sensitization.
Acute catarrhal conjunctivitis is a kind of common acute Epidemic ophthalmic caused by bacteriological infection.Its principal character is conjunctiva obviously hyperemia, purulence or mucosa purulent secretion, has spontaneous recovery to be inclined to.By the article (as towel, handkerchief, washbowl etc.) that contact patient's eyes secretions or tear were stained with, shaking hands with patient or rub eyes etc. with dirty hands all can be infected.Summer and autumn, because of heat, the easy growth and breeding of antibacterial, is very easy to cause and is very popular.The main feature of pink eye disease: simple eye or conjunctiva of both eyes is congested, have a large amount of mucosa purulent secretion, but generally do not affect one's power of vision.If treated not in time, what have then changes into chronic conjunctivitis.
Antimicrobial ointment or eye drip medicine is generally adopted to treat for infectious acute conjunctivitis clinically at present; symptom can be eliminated in 1 week to 6 weeks after medication usually; but the relapse rate of conjunctivitis is higher in therapeutic process; and a large amount of volatilizations of tear can be caused easily to cause xerophthalmia during eye drop use, drastically influence work and the life of patient.But because these Western medicine mostly have potential hepatotoxicity, and action target spot is single, and long-term taking can affect the health status of patient.Therefore research and develop the effective medicine of a kind of conjunctivitis to be of great practical significance.
The history of Chinese medicine conjunctivitis is of long standing and well established, and as an importance of modern oculopathy Comprehensive Treatment, more and more receives publicity in recent years.Zhang Yanli use in " Chinese medicine moves back the observation of curative effect of red collyrium to acute conjunctivitis " is moved back red collyrium flushing conjunctival sac treatment acute conjunctivitis and is achieved good clinical therapeutic efficacy.Wu Qingbo " herbal fumigation treatment vernal conjunctivitis in Functional observation " in disclose a kind of Chinese medicine compound (Herba Schizonepetae 10g, art thief 10g, Flos Chrysanthemi Indici 12g,
Periostracum Cicadae 10g, the Fructus Kochiae 109, Fructus Atriplicis Sibiricae 10g, Radix Aconiti Preparata 3g, Herba Asari 3g Herba Siegesbeckiae 15g, Radix Sophorae Flavescentis 10g, Zaocys l0g, Radix Platycodonis 10g, Semen Armeniacae Amarum 10g, Cortex Dictamni 12g, Radix Glycyrrhizae 12g), the effect taking afterwards and can have treatment and prevention of recurrence to vernal conjunctivitis first smoked by this medicine.
Summary of the invention
For the deficiency of current conjunctivitis clinical treatment medicine, first object of the present invention is to provide a kind of Chinese medicine composition for the treatment of acute catarrhal conjunctivitis, and this Chinese medicine composition has good therapeutic effect in treatment acute catarrhal conjunctivitis.Chinese medicine composition of the present invention, raw material primarily of following weight portion obtains: Rhizoma Polygoni Cuspidati 15 parts, Rhizoma Coptidis 6 parts, Herba Lycopodii 10 parts, Bulbus Lilii 10 parts, Herba Artemisiae Scopariae 10 parts, Rhizoma Acori Graminei 20 parts, the Pseudobulbus Bletillae (Rhizoma Bletillae) 20 parts, Radix Arnebiae (Radix Lithospermi) 10 parts, Herba Violae 5 parts, Caulis Spatholobi 5 parts, Flos Chrysanthemi Indici 10 parts.
The method preparing Chinese medicine composition of the present invention is as follows: each medical material getting above-mentioned components by weight percent, adds the 5-15 water doubly of medical material gross weight, soaks 10-60 minute, decoct 1-4 time, each 1-3 hour, filter, merging filtrate, filtrate reduced in volume is to the extractum of relative density 1.05-1.25, and this relative density is testing result at 60 c, and adding ethanol to alcohol content is 60-90% (v/v), leave standstill 24 hours, get supernatant, reclaim ethanol to concentrated, to obtain final product.The above-mentioned Chinese medicine composition of the present invention can be prepared into pharmaceutical preparation conventional clinically further, is preferably mixture, tablet, capsule.
The present invention also discloses a kind of purposes of above-mentioned Chinese medicine composition, and namely above-mentioned Chinese medicine composition merges the purposes in the medicine of cough at preparation treatment acute catarrhal conjunctivitis.By the antiinflammatory action investigating Chinese medicine composition xylol induced mice inflammatory model of the present invention, the embodiment of the present invention 4 confirms that Chinese medicine composition provided by the invention can have significant anti-inflammatory efficacy, its antiphlogistic effects is better than hydrocortisone, wherein high dose group and the antiphlogistic effects of middle dosage group have significant difference (P < 0.05) compared with hydrocortisone, this acts on comprehensively when showing traditional Chinese medicine composition for treating inflammatory conjunctivitis of the present invention, has obvious synergism, achieves unforeseeable curative effect of medication.To common pathogen fungistatic effect, the embodiment of the present invention 5 finds that Chinese medicine composition of the present invention can play inhibition to most pathogenic bacterium under very low crude drug concentration by investigating Chinese medicine composition of the present invention, have has a broad antifungal spectrum, treatment advantage that antimicrobial concentration is low when this shows the treatment of the present invention for bacterial acute catarrhal conjunctivitis.The embodiment of the present invention 6 proves that Chinese medicine composition of the present invention has significant antitussive effect.
In a word, the present invention compared with prior art, have the activity for the treatment of conjunctivitis very well, and the present invention is pure Chinese medicinal preparation, to human body particularly to liver avirulence.When the present invention uses as conjunctivitis medicine, drug effect is comprehensive, and conjunctivitis conditions of patients can be made rapidly to take a turn for the better, and has the effect of significant treatment cough; And Chinese medicine composition preparation of the present invention is simple, and substantially nontoxic, raw material is easy to get, and is suitable for popular use, has good potential applicability in clinical practice.
Detailed description of the invention
Further describe the present invention below by way of detailed description of the invention, but the present invention is not limited only to following examples.Within the scope of the invention or not departing from content of the present invention, spirit and scope, Chinese medicine composition of the present invention is suitably improved, replaces the identical component of effect, will become apparent to those skilled in the art that they are all deemed to be included within scope of the present invention.
Part I, the preparation of Chinese medicine composition of the present invention
Embodiment 1 Chinese medicine composition mixture of the present invention
Prescription: Rhizoma Polygoni Cuspidati 15 parts, Rhizoma Coptidis 6 parts, Herba Lycopodii 10 parts, Bulbus Lilii 10 parts, Herba Artemisiae Scopariae 10 parts, Rhizoma Acori Graminei 20 parts, the Pseudobulbus Bletillae (Rhizoma Bletillae) 20 parts, Radix Arnebiae (Radix Lithospermi) 10 parts, Herba Violae 5 parts, Caulis Spatholobi 5 parts, Flos Chrysanthemi Indici 10 parts.
Preparation method: each medical material getting above-mentioned components by weight percent, adds the water of 5 times of medical material gross weight, soaks 30 minutes, decoct 2 times, each 2 hours, filter, merging filtrate, filtrate reduced in volume is to the extractum of relative density 1.1, and this relative density is testing result at 60 c, adding ethanol to alcohol content is 75% (v/v), leaves standstill 24 hours, gets supernatant, recovery ethanol concentrates, and adds water to 1000ml, stirs evenly, subpackage, flowing steam sterilization 35min, obtains mixture.
Embodiment 2 Chinese medicine composition tablet of the present invention
Prescription: Rhizoma Polygoni Cuspidati 15 parts, Rhizoma Coptidis 6 parts, Herba Lycopodii 10 parts, Bulbus Lilii 10 parts, Herba Artemisiae Scopariae 10 parts, Rhizoma Acori Graminei 20 parts, the Pseudobulbus Bletillae (Rhizoma Bletillae) 20 parts, Radix Arnebiae (Radix Lithospermi) 10 parts, Herba Violae 5 parts, Caulis Spatholobi 5 parts, Flos Chrysanthemi Indici 10 parts.
Preparation method: each medical material getting above-mentioned components by weight percent, adds the water of 10 times of medical material gross weight, soaks 60 minutes, decoct 1 time, each 1 hour, filter, merging filtrate, filtrate reduced in volume is to the extractum of relative density 1.25, and this relative density is testing result at 60 c, adding ethanol to alcohol content is 80% (v/v), leave standstill 24 hours, get supernatant, reclaim ethanol to concentrated, vacuum drying, granulation, tabletting and get final product.
Embodiment 3 Chinese medicinal composition capsules of the present invention
Prescription: Rhizoma Polygoni Cuspidati 15 parts, Rhizoma Coptidis 6 parts, Herba Lycopodii 10 parts, Bulbus Lilii 10 parts, Herba Artemisiae Scopariae 10 parts, Rhizoma Acori Graminei 20 parts, the Pseudobulbus Bletillae (Rhizoma Bletillae) 20 parts, Radix Arnebiae (Radix Lithospermi) 10 parts, Herba Violae 5 parts, Caulis Spatholobi 5 parts, Flos Chrysanthemi Indici 10 parts.
Preparation method: each medical material getting above-mentioned components by weight percent, adds the water of 8 times of medical material gross weight, soaks 45 minutes, decoct 4 times, each 1.5 hours, filter, merging filtrate, filtrate reduced in volume is to the extractum of relative density 1.2, and this relative density is testing result at 60 c, adding ethanol to alcohol content is 90% (v/v), leaves standstill 24 hours, gets supernatant, reclaim ethanol to concentrated, vacuum drying, granulates, encapsulated and get final product.
Part II, the pharmacodynamics of Chinese medicine composition of the present invention is investigated
The antiinflammatory action of embodiment 4 Chinese medicine composition xylol of the present invention induced mice inflammatory model
Hydrocortisone is synthetic is also naturally occurring glucocorticoid, after hydrocortisone enters cell, activates cytoplasmic receptor, nucleus is entered after allosteric, be combined with DNA response element, cause suppression or the induction of genetic transcription, the expression of inflammation related proteins is changed.Hydrocortisone has stronger anti-inflammatory activity, is usually used in the treatment of arthritis, conjunctivitis clinically.
1, experimental technique:
50 KM mices, male and female half and half, body weight 25-30 gram, 5 groups are divided at random, i.e. dosage group in model control group, combination group high dose group, compositions, compositions low dose group, positive controls by body weight, often organize 10, each administration group mice gives following medicine respectively:
Model control group: gavage gives the normal saline of same volume;
Positive controls: gavage gives the hydrocortisone drug solution of 5mg/kg;
Chinese medicine composition high dose group: gavage gives 5g/kg embodiment 1 Chinese medicine composition, and Chinese medicine composition presses crude drug gauge;
Dosage group in Chinese medicine composition: gavage gives 2g/kg embodiment 1 Chinese medicine composition, and Chinese medicine composition presses crude drug gauge;
Chinese medicine composition low dose group: gavage gives 1g/kg embodiment 1 Chinese medicine composition, and Chinese medicine composition presses crude drug gauge;
Each administration group is administered once every day, successive administration 7d.Get dimethylbenzene 20 μ l after last administration, be applied to each mouse right ear.Get after 30 minutes and be respectively evenly applied to mouse right ear respectively by reagent 0.03ml, auris dextra is put to death after 3.5 hours to dimethylbenzene, measures each group of mice left and right ear method of double differences.Ear method of double differences assay method: place cuts two ears along auricle baseline, lays auricle with 8mm card punch at the same position of left and right ear, weighs, the ear method of double differences=auris dextra sheet weight-left auricle weight.The ear method of double differences can be used as evaluates antiinflammatory index.
Experimental result: measure the antiphlogistic effects that each experimental mice ear method of double differences evaluates each medication group medicine.Measurement result is in table 2.
Table 1 each experimental mice ear method of double differences compares
| Group | n | The ear method of double differences (mg) |
| Model control group | 10 | 8.20±1.18 |
| Positive controls | 10 | 6.24±1.51 * |
| Chinese medicine composition high dose group | 10 | 2.81±1.84 **## |
| Dosage group in Chinese medicine composition | 10 | 4.45±1.54 **# |
| Chinese medicine composition low dose group | 10 | 5.93±1.24 * |
Compare with model control group,
*p < 0.05; Compare with model control group,
*p < 0.01;
Compare with positive controls,
#p < 0.05; Compare with positive controls,
##p < 0.01.
Result display gives positive drug and Chinese medicine composition of the present invention all can obtain significant antiphlogistic effects, wherein the antiphlogistic effects of Chinese medicine composition high dose group of the present invention and positive controls have pole significant difference, Chinese medicine composition low dose group and positive controls have significant difference, and this shows that the high dose group of Chinese medicine composition of the present invention and the antiphlogistic effects of low dose group significantly will be better than positive controls.
The antibacterial experiment in vitro of embodiment 5 Chinese medicine composition of the present invention
The strain that this experiment uses and culture medium are respectively α-hemolytic streptococcus (32209), beta hemolytic streptococcus (32210), colon bacillus (44102), proteus vulgaris (49101), Salmonella paratyphi A (50001), shigella dysenteriae (51252), staphylococcus aureus [26111 (5)], hemophilus influenza (58529-4), nutrient agar (in tired pharmaceutical biological product calibrating institute); Opacity tube (Chinese bacterial turbidity standard, Chinese medicine biological combinations calibrating institute).
Antibacterial experiment in vitro: 1. prepare pastille agar plate.Tested material is pressed the culture medium of doubling dilution preparation different pharmaceutical concentration, heating, modulation is required pH value separately, and 121 DEG C of sterilizing 30min, are chilled to 45 DEG C.Pour into into aseptic flat board (plate d=
65mm, 10ml/ plate), finally make the extension rate containing tested material stock solution (2g/ml) in culture medium be respectively l:2,1:4 ... 1:1024.Do respective blank culture medium simultaneously.2. inoculate.Get the bacterium in young age reaching the third generation, point
Be not the bacterium liquid to be checked of 108cfu/ml by standard opacity tube corrected concentrations with 0.9% sodium chloride solution, be inoculated in the respective pastille agar surface of different doubling dilution respectively, Simultaneous vaccination parallel point 3 point, make at often containing 2 one bacterium liquid.The liquid-drop diameter of each vaccination is 5-8mm.After point to be seeded drying, upset is dull and stereotyped cultivates 20h observed result (simultaneously doing blank) in 36 DEG C of constant incubators.3. criterion.Not occur that minimum dilution tested material concentration on the agar plate of bacterium colony is for its minimum inhibitory concentration (MIC).
In this experiment, the minimal inhibitory concentration of Chinese medicine composition to each pathogenic strain is as shown in table 2:
Table 2 Chinese medicine composition of the present invention is to the minimal inhibitory concentration of each pathogenic strain
Result shows, and Chinese medicine composition of the present invention all has good fungistatic effect to most pathogenic bacterium, and this, for being the most easily subject to the eyes conjunctiva of extraneous infection, has very important therapeutic potential.
Embodiment 6 Chinese medicine composition of the present invention is for the impact of mouse cough model
Get Kunming mouse, be divided into 2 groups at random, i.e. blank group, Chinese medicine composition group and positive drug group, often organize 10, according to corresponding dosed administration, last administration 1 hour, by 500ml beaker back-off in desktop, injects cotton balls with syringe by 28% ammonia 2ml, be placed in the beaker of back-off, after 30 seconds, take out cotton swab, put into mice respectively, observing the coughre flex of mice, recording from putting into the time of mice to mice generation coughre flex and the cough number of times of cough latent period and 3 minutes mices.Wherein Chinese medicine composition prepares according to preparation method described in embodiment 1, statistical method: application SPSS13.0 software kit carries out statistical procedures.Data acquisition mean ± standard deviation represents, compares employing variance analysis between group.
Table 3 Chinese medicine composition of the present invention causes the impact coughing mouse cough incubation period and cough number of times for strong aqua ammonia
| Test medicine | Dosage | Cough latent period (s) | Cough number of times in 3min |
| Blank group | - | 35.3±3.4 | 48.2±3.5 |
| Chinese medicine composition high dose group | 5g/kg | 44.1±4.8 △△*# | 36.1±2.1 △△*# |
| Dosage group in Chinese medicine composition | 2g/kg | 42.4±3.6 △* | 38.7±3.0 △* |
| Chinese medicine composition low dose group | 1g/kg | 40.7±3.2 △* | 40.1±2.8 △* |
| Positive drug group | Gentamycin 30mg/kg | 40.8±3.4△ | 40.1±2.9△ |
Claims (4)
1. the Chinese medicine composition for the treatment of acute catarrhal conjunctivitis and merging cough, it is characterized in that it obtains primarily of the raw material of following weight portion: Rhizoma Polygoni Cuspidati 15 parts, Rhizoma Coptidis 6 parts, Herba Lycopodii 10 parts, Bulbus Lilii 10 parts, Herba Artemisiae Scopariae 10 parts, Rhizoma Acori Graminei 20 parts, the Pseudobulbus Bletillae (Rhizoma Bletillae) 20 parts, Radix Arnebiae (Radix Lithospermi) 10 parts, Herba Violae 5 parts, Caulis Spatholobi 5 parts, Flos Chrysanthemi Indici 10 parts.
2. Chinese medicine composition as claimed in claim 1, is characterized in that described Chinese medicine composition is mixture, tablet or capsule.
3. prepare the method for Chinese medicine composition as claimed in claim 1 or 2 for one kind, it is characterized in that it comprises the following steps: get each medical material, add the 5-15 water doubly of medical material gross weight, soak 10-60 minute, decoct 1-4 time, each 1-3 hour, filter, merging filtrate, filtrate reduced in volume is to the extractum of relative density 1.05-1.25, this relative density is testing result at 60 c, adding ethanol to alcohol content is 60-90% (v/v), leaves standstill 24 hours, gets supernatant, reclaim ethanol to concentrated, to obtain final product.
4. Chinese medicine composition as claimed in claim 1 or 2 merges the purposes in cough medicine at preparation treatment acute catarrhal conjunctivitis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510389925.4A CN104887973A (en) | 2015-07-04 | 2015-07-04 | Traditional Chinese medicine composition for treating acute catarrhal conjunctivitis with cough |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510389925.4A CN104887973A (en) | 2015-07-04 | 2015-07-04 | Traditional Chinese medicine composition for treating acute catarrhal conjunctivitis with cough |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104887973A true CN104887973A (en) | 2015-09-09 |
Family
ID=54021215
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510389925.4A Pending CN104887973A (en) | 2015-07-04 | 2015-07-04 | Traditional Chinese medicine composition for treating acute catarrhal conjunctivitis with cough |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104887973A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107970259A (en) * | 2017-12-19 | 2018-05-01 | 魏立梅 | A kind of medical composition and its use for treating acute pulpitis |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102836228A (en) * | 2012-10-10 | 2012-12-26 | 陈兴旺 | Chinese medicinal composition for treating conjunctivitis and preparation method and application thereof |
| CN104257794A (en) * | 2014-09-17 | 2015-01-07 | 卞国良 | Traditional Chinese medicinal composition for tonifying spleen and removing stagnation and preparation method thereof |
| CN104547637A (en) * | 2014-12-30 | 2015-04-29 | 黎细乐 | Traditional Chinese medicine composition for treating chronic aplastic anemia complicated with pulmonary infection |
| CN104547575A (en) * | 2014-12-31 | 2015-04-29 | 曾子维 | Traditional Chinese medicinal composition for treating capillary bronchitis and induced diarrhea and method for preparing composition |
-
2015
- 2015-07-04 CN CN201510389925.4A patent/CN104887973A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102836228A (en) * | 2012-10-10 | 2012-12-26 | 陈兴旺 | Chinese medicinal composition for treating conjunctivitis and preparation method and application thereof |
| CN104257794A (en) * | 2014-09-17 | 2015-01-07 | 卞国良 | Traditional Chinese medicinal composition for tonifying spleen and removing stagnation and preparation method thereof |
| CN104547637A (en) * | 2014-12-30 | 2015-04-29 | 黎细乐 | Traditional Chinese medicine composition for treating chronic aplastic anemia complicated with pulmonary infection |
| CN104547575A (en) * | 2014-12-31 | 2015-04-29 | 曾子维 | Traditional Chinese medicinal composition for treating capillary bronchitis and induced diarrhea and method for preparing composition |
Non-Patent Citations (4)
| Title |
|---|
| 翁维良 等: "《临床中药学》", 31 May 1988, 河南科学技术出版社 * |
| 谢明 等: "《中草药辨识图谱与应用》", 31 January 2015, 辽宁科学技术出版社 * |
| 赵家良: "《眼科》", 31 October 2014, 中国医药科技出版社 * |
| 陆鹏飞 等: "《陆氏中医诊治验方》", 30 April 2014, 中医古籍出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107970259A (en) * | 2017-12-19 | 2018-05-01 | 魏立梅 | A kind of medical composition and its use for treating acute pulpitis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102578169B (en) | Chinese herb biological disinfectant | |
| CN104488986A (en) | Traditional Chinese medicine sterilizing liquid for clinical laboratory | |
| CN102470117B (en) | Composition comprising benzoic acid in combination with organic acid preservatives as active components and use thereof | |
| CN102836228B (en) | Chinese medicinal composition for treating conjunctivitis and preparation method and application thereof | |
| CN102836367B (en) | Bacteria-resisting, inflammation-diminishing and itching-relieving traditional Chinese medicine composition and preparation method and application thereof | |
| CN101664446A (en) | Relinging extractum and preparation method and application | |
| CN102716223A (en) | Chinese medicinal composition for treating upper respiratory tract infection and preparation method thereof | |
| CN104013846A (en) | Traditional Chinese medicine composition for treating dental ulcer and application thereof | |
| CN103830469A (en) | Chinese medicinal composition for treating purulent meningitis and application thereof | |
| CN103251844A (en) | Tablet for clearing heat from throat and wetting throat | |
| CN104721241A (en) | Hibiscus rosa-sinensis flower bud extracts and application thereof | |
| CN103961412A (en) | Traditional Chinese medicine composition as well as preparation method and application thereof | |
| CN103142683A (en) | Sophora alopecuroide total alkaloid-containing traditional Chinese medicine perfusion fluid for treating bovine mastitis and endometritis as well as preparation method of perfusion fluid | |
| CN106309746A (en) | Traditional Chinese medicine composition, preparation method thereof and oral health product | |
| CN104887973A (en) | Traditional Chinese medicine composition for treating acute catarrhal conjunctivitis with cough | |
| CN102988844A (en) | Gynaecological gel and extraction method thereof | |
| CN103372076A (en) | Medicine for treating diseases caused by propionibacterium acnes and application of sanguisorba officinalis and/or sanguisorba officinalis extract | |
| CN103251691B (en) | Chinese medicine formula for treating bovine mastitis as well as extract and preparation thereof | |
| CN106334034A (en) | Traditional Chinese medicine compositon, nose drop containing same and application thereof | |
| CN114177231A (en) | Antipyretic pharmaceutical composition, antipyretic gel and preparation method | |
| CN102743432A (en) | Application of patchouli oil in preparation of medicines used for treating colpitis | |
| CN103271983B (en) | A kind of endometritis and colpitic perfusion liquid, its preparation method and application for the treatment of pig | |
| CN104055981B (en) | One kind treats bronchiectasic Chinese medicine composition | |
| CN100536893C (en) | Compound Chinese medicine comprising parasitic loranthus and mistletoe and its use | |
| CN104207130B (en) | A kind of food of clearing heat and freeing strangury, health products or pharmaceutical composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150909 |